AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Biotech Insights: Future of GLP-1s, AI's Impact, and Tariffs
ByAinvest
Wednesday, Sep 24, 2025 4:07 pm ET1min read
Citi Research's Anne Malone and Geoff Meacham discuss the future of GLP-1s, the impact of AI on biotech, and potential effects of tariffs. Malone, head of North America Equity Research, and Meacham, U.S. pharma and biotech research analyst, provide insights on the biotech industry.
UBS has revised its global GLP-1 sales forecast for 2030, slashing it from over $150 billion to $130 billion [1]. The downgrade is attributed to weaker-than-expected data from next-generation assets and compounded product disruptions in the US market. Despite the adjustment, UBS maintains that the GLP-1 and incretin market is one of the most exciting growth drivers in global pharma, projecting a 19% sales CAGR between 2024 and 2030. The obesity treatment segment is expected to see the largest expansion, growing from 4.4 million patients in 2024 to 34 million by 2030.TNF Pharmaceuticals, Inc. has announced a collaboration with Renova Health to explore the effects of its lead candidate, isomyosamine (MYMD-1), on GLP-1-induced sarcopenia and frailty. The fully funded study will evaluate TNF-α levels in patients receiving GLP-1 agonists Wegovy or Ozempic who show signs of increased inflammation associated with sarcopenia [2]. This trial aims to address a significant issue in GLP-1 therapies, as up to 40% of the total weight lost by GLP-1 patients is lean body mass, including skeletal muscle mass.
Citi Research's Anne Malone and Geoff Meacham recently discussed the future of GLP-1s, the impact of AI on biotech, and potential effects of tariffs. Malone, head of North America Equity Research, and Meacham, U.S. pharma and biotech research analyst, provided insights into the biotech industry's prospects, including the role of AI in drug discovery and development. They also touched on the potential challenges posed by tariffs and how they might impact the industry.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet